Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis
Pemphigus Vulgaris
Granulomatosis With Polyangiitis
Systemic Lupus Erythematosus

Interventions

DRUG: AB-101
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

IRIS Research and Development, LLC

Collaborators

[object Object]